Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 11, Issue 1, Pages 124-126Publisher
CIG MEDIA GROUP, LP
DOI: 10.3816/CLML.2011.n.027
Keywords
-
Categories
Ask authors/readers for more resources
Advanced age is one of the variables more frequently considered to be associated with an adverse prognosis in Waldenstrom's macroglobulinemia (WM). In a series of 238 symptomatic and asymptomatic WM patients, we retrospectively identified an age cut-off distinguishing two groups of patients with different outcome in terms of overall survival (OS), disease-specific survival (DSS) and treatment-free survival (TFS). Although for the OS the best cut-off was identified at 65 years with shorter OS for elderly patients, no difference was detected in terms of DSS between the two groups. Furthermore, patients over 65 years showed a longer TFS compared with patients under 65 years. Clinical and laboratory disease characteristics did not significantly differ between the two groups of patients except for beta M-2 level. Therefore, the poorer survival of patients over 65 years at diagnosis should probably be attributed to the higher number of no disease-related deaths and is independent from WM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available